Navigation Links
Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Date:12/8/2012

COLUMBUS, Ohio Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) presented these findings today (12/8) at the 54th Annual Meeting of the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

The study found that response to therapy was high across cohorts, with 71 percent of previously untreated older patients experiencing a complete or partial response at either treatment dose (420mg and 840mg). The same response was observed in 67 percent of the relapsed patients and half (50%) of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

"These findings are truly exciting because they demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL that produces a high rate of durable remissions the remissions last months on end," Byrd says. "The drug is effective in part because patients are willing to stay on treatment since the side effects are very tolerable," he states.

Only non-severe side effects, including diarrhea, fatigue, chest infection, rash, nausea, joint pain and infrequent and transient low blood counts were observed. Investigators found no evidence of c
'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EzCheckPrinting Updated with New Category Feature to Simplify Check Printing and Tax Reporting
2. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
3. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
4. USC Norris cancer research ranks among top clinical advances for 2012
5. American Society of Clinical Oncology issues annual report on state of clinical cancer science
6. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
7. Study finds link between access to online health information and use of clinical services
8. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Molecular portraits of tumours match patients with trials in everyday clinical practice
10. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
11. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 -- Only about half of all pregnant ... leaving thousands of moms-to-be and their babies at increased risk ... should be a routine part of prenatal care," said Edward ... providers should offer their pregnant patients a flu shot each ... it." , A report by the U.S. Centers for Disease ...
(Date:9/18/2014)... German . In ... fight a pathogen tooth and nail, but rather tolerate it to ... of tolerance is that the disease only progresses very slowly ... pathogen load. , Roland Regoes, a senior scientist at ETH Zurich,s ... He set about investigating whether there are infected people who are ...
(Date:9/18/2014)... CRDF Global released today its ... edition – rich with videos, images and interactive ... Global empowers scientists and innovators around the world. ... foundation and individual supporters, CRDF Global reaches across ... training and entrepreneurship. , The Annual Report highlights ...
(Date:9/18/2014)... Africa (PRWEB) September 18, 2014 Phela ... adopt the HABIT™ Program in South Africa. ... Health and Wellness, and distributed in South Africa by ... the HABIT program, which has been tailored to address ... HABIT™ focuses on behavior modification and chronic disease prevention. ...
(Date:9/18/2014)... new expert panel report, Improving Medicines for Children ... Canadian Academies, addresses the importance of developing safe ... half of Canada,s seven million children use at ... is done off-label (i.e. the prescription differs from ... have historically been excluded in drug research and ...
Breaking Medicine News(10 mins):Health News:Flu vaccine for expectant moms a top priority 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Improving medicines for children in Canada 2
... Event at Penn State Hershey to Launch 2008 ... Thousands of,Pennsylvania taxpayers who participate in the ... Research deserve recognition for the,thousands of dollars in ... year. On Monday, February 11 at 9:30 a.m., ...
... Montreal, 6 February 2008 - A recent study by ... Health Centre research Institute, sheds some new light on ... Hastons study is pointing at genetics as contributing to ... implications in changing therapeutic practices. The article was published ...
... ) announced today that its Chief Executive Officer, Mark,McAndrew, and Chief Financial Officer, ... Conference in,New York City. Torchmark,s presentation is scheduled to begin at 2:20 p.m.,EST., ... The presentation will be webcast live at:, ... http://www.torchmarkcorp.com ...
... Group on,Health (NBGH) and the Office of Minority Health ... 2008 at 1:30 p.m. EST to announce a new,initiative ... improve the quality of health care for a culturally ... and public health,together to develop guidance and strategies for ...
... Tobacco-Free Kids, WASHINGTON, Feb. 7 The World ... clear both,the devastating scope of the global tobacco epidemic ... the world today - and the fact that it ... presents the first comprehensive picture of what the world,s ...
... February 19, 9 a.m. - 5 p.m.), SCOTTSDALE, ... Children,s Dental Health Month. Dr. Lee Weinstein, a ... Associates for Kids Only, will be offering a Free ... a.m. until 5 p.m., The first 30 patients that ...
Cached Medicine News:Health News:The Pennsylvania Breast Cancer Coalition Announces 2008 Breast Cancer Income Tax Check-Off Grant Recipients 2Health News:Landmark WHO Report on Global Tobacco Epidemic Should Spur Urgent Action by Nations to Implement Proven Solutions 2Health News:Landmark WHO Report on Global Tobacco Epidemic Should Spur Urgent Action by Nations to Implement Proven Solutions 3Health News:Free Children's Dental Day; Expert Source on Children's Dental Health Available 2
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
(Date:9/18/2014)... 18, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... focused on discovering, developing and commercializing innovative ... RNA-targeted technologies, today announced that the Company,s President ... Cauwenbergh , will present at the 7 ... Wednesday, September 24, 2014 at 11:20 a.m. ...
(Date:9/17/2014)... DALLAS , Sept. 17, 2014 /PRNewswire-iReach/ -- ... Methyl Methacrylate (MMA) Industry" and "2014 Market Research ... research reports to its store. Photo ... Market Research Report on Global Methyl Methacrylate (MMA) ... on China and Global ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 2Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 3Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 4Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: